论文部分内容阅读
CS－045系日本三共公司开发的降血糖药，与磺酸豚类药物不同，不是通过胰脏分泌胰岛素，而是通过增强胰岛素在外周的作用、抑制肝脏过度的糖原异生未达到降血糖作用。动物实验表明，它还具有降低血中甘油三酯的作用。非胰岛素依赖性糖尿病患者口服本品，每日200～800mg，连续给
CS-045 is a hypoglycemic drug developed by Japan Sankyo Co., which is different from sulfonated dolphin drugs. It does not achieve insulin-lowering through the pancreas but inhibits hypoglycemia through excessive insulin action on the periphery and suppression of excessive gluconeogenesis in the liver effect. Animal experiments show that it also has the role of reducing blood triglycerides. Non-insulin-dependent diabetes patients oral this product daily 200 ~ 800mg, continuous to give